Abstract: Cycloheximide is a naturally occurring glutarimide-containing polyketide first isolated from Streptomyces griseus. It is a well-known and potent inhibitor of eukaryotic protein synthesis that functions by blocking translation elongation at the 80S ribosome. While it exhibits a broad spectrum of pharmacological activities, including antifungal, antiviral, and anti-leukemic properties, its severe toxicity has historically precluded its clinical application in humans. However, recent advances in high-resolution cryo-electron microscopy (cryo-EM) have elucidated the precise molecular interactions between cycloheximide and the human ribosome. This structural insight has revitalized interest in the compound, enabling structure-guided drug design to develop novel derivatives with significantly enhanced anti-cancer potency and potentially wider therapeutic windows. This review summarizes the pharmacological activity, molecular mechanism of action, structure-activity relationships, current limitations, and future therapeutic perspectives of cycloheximide, with a specific focus on protein degradation and stability.
1. Introduction
Cycloheximide (originally known as actidione) is the first identified member of the glutarimide-containing polyketides (GPs), isolated from Streptomyces griseus in 1947 [1][2]. The biosynthesis of this compound is governed by a trans-AT polyketide synthase (AT-less PKS) [1]. Structurally, cycloheximide is characterized by a bipartate framework consisting of a six-membered glutarimide ring (2,6-piperidinedione) and a 3,5-dimethyl-2-oxocyclohexyl side chain attached at the C4 position [1]. The molecule possesses four distinct chiral centers, the stereoconfiguration of which is critical to its biological function [1]. For decades, cycloheximide has been extensively utilized as a fundamental molecular and cellular biology reagent to study protein synthesis, transcription, and cellular stress responses in eukaryotic cells [1][2].
2. Pharmacological Activity
Cycloheximide exhibits a diverse array of biological activities. It displays strong antifungal properties against plant fungi and possesses significant antiviral activity against various RNA and DNA viruses, including HIV-1, influenza virus, and Herpes Simplex Virus (HSV) [1]. In the context of oncology, cycloheximide has demonstrated preferential anti-proliferative activity in leukemic cells compared to normal cells, highlighting its potential as a lead compound for anti-cancer drug design [2].
Furthermore, cycloheximide is a critical tool in the study of cellular stress responses and protein stability. Because it inhibits translation elongation, it is used experimentally to differentiate between various cytoplasmic ribonucleoprotein entities. For instance, cycloheximide treatment prevents the formation of stress granules (SGs) but does not dismantle assemblysomes (paused ribosome-nascent chain complexes), as translation in the latter is already stalled [3].
3. Molecular Mechanism of Action
The primary mechanism of action of cycloheximide is the potent inhibition of eukaryotic protein synthesis. It achieves this by interfering with the translocation step during translation elongation [1][2]. Cycloheximide is highly specific to eukaryotes and has no inhibitory effect on bacterial protein synthesis, such as in E. coli [2].
At the molecular level, cycloheximide targets the 60S subunit of the eukaryotic 80S cytosolic ribosome [1]. High-resolution cryo-electron microscopy (cryo-EM) at 3.6 Å resolution has visualized the exact binding pocket of cycloheximide within the human ribosome. The molecule inserts itself similarly to an E-site tRNA, positioning itself between ribosomal RNA residues G4370 and G4371, thereby preventing the tRNA from leaving the E-site and locking the ribosome in a state that halts peptide chain extension [1][2].
4. Structure-Activity Relationship (SAR)
Extensive structure-activity relationship (SAR) studies have identified the critical molecular features required for cycloheximide's bioactivity:
Glutarimide Ring: The six-membered glutarimide ring is structurally analogous to uracil derivatives. This similarity allows the molecule to act as a carrier that interacts with uracil and thymidine nucleoside transporter receptors, facilitating efficient passage across cell membranes and the blood-brain barrier [1].
Chirality: The four chiral centers are absolutely essential for maintaining activity. Any modification to these chiral centers results in a significant loss of biological function; they must remain identical to the natural compound [2].
Functional Groups: The 6-OH and 8-C=O groups have been identified as specific antiviral active sites [1].
Cyclohexanone Moiety Modifications: Recent rational design efforts have shown that altering the cyclohexanone moiety can enhance activity. Replacing a methyl group with a butyl chain in this region does not notably decrease activity. More importantly, incorporating electrophilic groups, such as a benzyl ester, improves protein synthesis inhibition by an order of magnitude by enabling new interactions with nearby ribosomal lysine residues [2].
5. Current Limitations
The most significant limitation of cycloheximide is its extreme toxicity in eukaryotes, which is currently too high to permit its application as a therapeutic agent in humans [2]. Historically, scientific interest in developing cycloheximide as a drug declined because early empirical attempts to synthesize analogues in the 1960s failed to yield compounds with improved bioactivity or reduced toxicity [2]. Most structural modifications led to a complete loss of activity, cementing the belief that the molecule was too toxic and structurally rigid for clinical optimization [2].
6. Future Perspectives
The advent of high-resolution cryo-EM has revolutionized the therapeutic prospects of cycloheximide by enabling structure-guided drug design [2]. Structural elucidation of the human 80S ribosome-cycloheximide complex has revealed unexploited spatial pockets. For example, the space between cycloheximide and the eukaryote-specific ribosomal protein eL42 can be filled by rationally designed derivatives to form novel interactions with residues such as Lys53, Pro54, or Phe56 [2].
Exploiting this structural data, recent ongoing projects have synthesized approximately 70 new cycloheximide derivatives. Among these, five novel molecules have demonstrated a 50- to 100-fold improvement in anti-leukemic activity compared to parental cycloheximide, alongside a higher inhibitory effect on the ribosome [2]. These derivatives are currently undergoing rigorous in vitro and in vivo characterization to evaluate their toxicity profiles and establish viable therapeutic windows, offering renewed hope for targeting the human ribosome in cancer therapy [2].
